Evidence-based selection of inhaled corticosteroid for treatment of chronic asthma (Q36761823)

16 August 2017

1 reference

title

Evidence-based selection of inhaled corticosteroid for treatment of chronic asthma (English)

1 reference

16 August 2017

1 reference

Anwar K Abdullah

1

1 reference

16 August 2017

Salman Khan

series ordinal

2

1 reference

16 August 2017

language of work or name

English

0 references

publication date

1 January 2007

1 reference

16 August 2017

1 reference

16 August 2017

volume

44

1 reference

16 August 2017

issue

1

1 reference

16 August 2017

page(s)

1-12

1 reference

Transcription factors and asthma

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1080/02770900601118099

Systemic adverse effects of inhaled corticosteroid therapy: A systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02770900601118099

The local side effects of inhaled corticosteroids: current understanding and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02770900601118099

Grading strength of recommendations and quality of evidence in clinical guidelines: report from an american college of chest physicians task force

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02770900601118099

Inhaled corticosteroids: past lessons and future issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02770900601118099

Risk-benefit value of inhaled glucocorticoids: a pharmacokinetic/pharmacodynamic perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02770900601118099

Pulmonary drug delivery. Part I: Physiological factors affecting therapeutic effectiveness of aerosolized medications

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02770900601118099

Efficacy and safety of inhaled corticosteroids. New developments

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02770900601118099

Hydrofluoroalkane formulations of inhaled corticosteroids for the treatment of asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02770900601118099

Comparison of potency of inhaled beclomethasone and budesonide in New Zealand: retrospective study of computerised general practice records

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02770900601118099

Efficacy of budesonide Turbuhaler compared with that of beclomethasone dipropionate pMDI in Japanese patients with moderately persistent asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02770900601118099

Effects of mometasone furoate dry powder inhaler and beclomethasone dipropionate hydrofluoroalkane and chlorofluorocarbon on the hypothalamic-pituitary-adrenal axis in asthmatic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02770900601118099

Mometasone furoate: efficacy and safety in moderate asthma compared with beclomethasone dipropionate

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02770900601118099

Dose-ranging study of a new steroid for asthma: mometasone furoate dry powder inhaler

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02770900601118099

Rapid effect of inhaled steroids on nocturnal worsening of asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02770900601118099

Cost analysis of the use of inhaled corticosteroids in the treatment of asthma: a 1-year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02770900601118099

Improved safety with equivalent asthma control in adults with chronic severe asthma on high-dose fluticasone propionate

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02770900601118099

Improvement in health-related quality of life with fluticasone propionate compared with budesonide or beclomethasone dipropionate in adults with severe asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02770900601118099

Oral candidiasis associated with inhaled corticosteroid use: comparison of fluticasone and beclomethasone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02770900601118099

Cough and wheezing from beclomethasone dipropionate aerosol are absent after triamcinolone acetonide

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02770900601118099

Local side-effects of inhaled corticosteroids in asthmatic children: influence of drug, dose, age, and device

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02770900601118099

Systemic effect comparisons of six inhaled corticosteroid preparations

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02770900601118099

A randomized, double-blind comparison of beclomethasone dipropionate extrafine aerosol and fluticasone propionate

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02770900601118099

Adrenal Function as Assessed by Low-Dose Adrenocorticotropin Hormone Test Before and After Switching from Inhaled Beclomethasone Dipropionate to Inhaled Fluticasone Propionate

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02770900601118099

Adrenal function and high dose inhaled corticosteroids for asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02770900601118099

Fluticasone propionate 1 mg daily and beclomethasone dipropionate 2 mg daily: a comparison over 1 yr.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02770900601118099

Effects of 2 inhaled corticosteroids on growth: results of a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02770900601118099

Fluticasone propionate 750 micrograms/day versus beclomethasone dipropionate 1500 micrograms/day: comparison of efficacy and adrenal function in paediatric asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02770900601118099

Safety and efficacy of fluticasone and beclomethasone in moderate to severe asthma. Belgian Multicenter Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02770900601118099

Comparison of fluticasone propionate with beclomethasone dipropionate in moderate to severe asthma treated for one year. International Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02770900601118099

A comparison of the efficacy and safety of a half dose of fluticasone propionate with beclamethasone dipropionate and budesonide in childhood asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02770900601118099

Airway and systemic effects of hydrofluoroalkane fluticasone and beclomethasone in patients with asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02770900601118099

Comparison of two high dose corticosteroid aerosol treatments, beclomethasone dipropionate (1500 micrograms/day) and budesonide (1600 micrograms/day), for chronic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02770900601118099

One-year trial on safety and normal linear growth with flunisolide HFA in children with asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02770900601118099

Inhaled corticosteroids effects on bone in asthmatic and COPD patients: a quantitative systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02770900601118099

Bone and collagen turnover during treatment with inhaled dry powder budesonide and beclomethasone dipropionate

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02770900601118099

Relationship between systemic corticosteroid exposure and growth velocity: development and validation of a pharmacokinetic/pharmacodynamic model

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02770900601118099

Short-term growth during treatment with inhaled fluticasone propionate and beclomethasone dipropionate

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02770900601118099

Therapeutic significance of distal airway inflammation in asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02770900601118099

Effectiveness of budesonide administered via dry-powder inhaler versus triamcinolone acetonide administered via pressurized metered-dose inhaler for adults with persistent asthma in managed care settings

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02770900601118099

Fluticasone alone or in combination with salmeterol vs triamcinolone in asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02770900601118099

Patient satisfaction with budesonide Turbuhaler versus triamcinolone acetonide administered via pressurized metered-dose inhaler in a managed care setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02770900601118099

Effects of the inhaled corticosteroids fluticasone propionate, triamcinolone acetonide, and flunisolide and oral prednisone on the hypothalamic-pituitary-adrenal axis in adult patients with asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02770900601118099

A study comparing the clinical pharmacokinetics, pharmacodynamics, and tolerability of triamcinolone acetonide HFA-134a metered-dose inhaler and budesonide dry-powder inhaler following inhalation administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02770900601118099

Dose-response comparison of systemic bioactivity with inhaled budesonide and triamcinolone acetonide in asthmatic adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02770900601118099

Effects of fluticasone propionate, triamcinolone acetonide, prednisone, and placebo on the hypothalamic-pituitary-adrenal axis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02770900601118099

Cost effectiveness of fluticasone propionate and flunisolide in the treatment of corticosteroid-naive patients with moderate asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02770900601118099

Comparison of the efficacy of inhaled fluticasone propionate, 880 microg/day, with flunisolide, 1500 microg/day, in moderate-to-severe persistent asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02770900601118099

Suppression of hypothalamic-pituitary-adrenal axis activity with inhaled flunisolide and fluticasone propionate in adult asthma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02770900601118099

Budesonide once versus twice-daily administration: meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02770900601118099

Asthma controller therapy during pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02770900601118099

Protection by budesonide and fluticasone on allergen-induced airway responses after discontinuation of therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02770900601118099

Fluticasone propionate and budesonide do not influence bone metabolism in the long term treatment of asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02770900601118099

Comparison of the efficacy and safety of mometasone furoate dry powder inhaler to budesonide Turbuhaler

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02770900601118099

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02770900601118099

Comparison of the efficacy of ciclesonide 160 microg QD and budesonide 200 microg BID in adults with persistent asthma: a phase III, randomized, double-dummy, open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02770900601118099

Comparative efficacy of once-daily ciclesonide and budesonide in the treatment of persistent asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02770900601118099

Cost-efficacy comparison of inhaled fluticasone propionate and budesonide in the treatment of asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02770900601118099

Pharmacokinetics and systemic activity of fluticasone via Diskus and pMDI, and of budesonide via Turbuhaler

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02770900601118099

Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02770900601118099

Comparison of the systemic effects of fluticasone propionate and budesonide given by dry powder inhaler in healthy and asthmatic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02770900601118099

Systematic review of the dose-response relation of inhaled fluticasone propionate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02770900601118099

Iatrogenic Cushing's syndrome with osteoporosis and secondary adrenal failure in human immunodeficiency virus-infected patients receiving inhaled corticosteroids and ritonavir-boosted protease inhibitors: six cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02770900601118099

Dose-ranging study of mometasone furoate dry powder inhaler in the treatment of moderate persistent asthma using fluticasone propionate as an active comparator

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02770900601118099

Efficacy and safety of mometasone furoate dry powder inhaler vs fluticasone propionate metered-dose inhaler in asthma subjects previously using fluticasone propionate

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02770900601118099

Airway and systemic effects of hydrofluoroalkane formulations of high-dose ciclesonide and fluticasone in moderate persistent asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02770900601118099

Effects of inhaled ciclesonide and fluticasone propionate on cortisol secretion and airway responsiveness to adenosine 5'monophosphate in asthmatic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02770900601118099

Effect of ciclesonide and fluticasone on hypothalamic-pituitary-adrenal axis function in adults with mild-to-moderate persistent asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02770900601118099

Comparison of the oropharyngeal deposition of inhaled ciclesonide and fluticasone propionate in patients with asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02770900601118099

Adrenal suppression with dry powder formulations of fluticasone propionate and mometasone furoate

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02770900601118099

Mometasone furoate has minimal effects on the hypothalamic-pituitary-adrenal axis when delivered at high doses

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02770900601118099

Preclinical profile of ciclesonide, a novel corticosteroid for the treatment of asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02770900601118099

Ciclesonide, a novel inhaled steroid, does not affect hypothalamic-pituitary-adrenal axis function in patients with moderate-to-severe persistent asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02770900601118099

Survey of adrenal crisis associated with inhaled corticosteroids in the United Kingdom

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02770900601118099

Significant receptor affinities of metabolites and a degradation product of mometasone furoate

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02770900601118099

Inhaled mometasone furoate: a review of its use in adults and adolescents with persistent asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02770900601118099

Effects of mometasone furoate given once daily in the evening on lung function and symptom control in persistent asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02770900601118099

Efficacy and safety of mometasone furoate administered once-daily in the evening in patients with persistent asthma dependent on inhaled corticosteroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02770900601118099

Fluticasone given once versus twice a day: meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02770900601118099

Population pharmacokinetics and pharmacodynamics of ciclesonide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02770900601118099

Model-based covariate pharmacokinetic analysis and lack of cortisol suppression by the new inhaled corticosteroid ciclesonide using a novel cortisol release model

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02770900601118099

Maintenance of asthma control by once-daily inhaled ciclesonide in adults with persistent asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02770900601118099

Once-daily ciclesonide improves lung function and is well tolerated by patients with mild-to-moderate persistent asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02770900601118099

Effect of low-dose ciclesonide on allergen-induced responses in subjects with mild allergic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02770900601118099

10.1080/02770900601118099

21 January 2018

Identifiers

DOI

1 reference

16 August 2017

1 reference